Drugs / CD19 targeted CAR T Cell Therapy
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04745559 | Feb 2021 → Jul 2025 overdue | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 targeted CAR T Cell Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04745559 ↗ |
| Modality | Cell therapy | “CD19-targeted CAR T cell therapy” NCT04745559 ↗ |
| Target | CD19 | “retarget cells against CD19 protein on the surface of B cells” NCT04745559 ↗ |